Clinicians will encounter more patients at risk for CHF as the population ages and cardiovascular risk factors become more prevalent.
Researchers also observed no difference in 30-day mortality rates between patients in the ICU and those who received regular inpatient care in another hospital unit.
Ambulatory high-dose intravenous diuretic therapy could be cost saving compared with hospitalization for intravenous loop diuretic therapy.
Some individual NSAIDs may be linked to increased risk of hospital admission for heart failure.
The American Heart Association has published a scientific statement that outlines which medications cause or exacerbate heart failure.
At 16 months, 30.3% of patients either died or experienced worsening heart failure.
The FDA will add warnings about heart failure risk to the labels of type 2 diabetes medicines containing saxagliptin and alogliptin.
Patients with coronary artery disease who were previously not considered candidates for CABG may benefit from the surgery.
Regardless of history of heart failure, incretin-based medications are not associated with an increased risk for hospitalization due to heart failure.
Patients who were obese and underwent bariatric surgery saw a significant reduction in heart failure-related exacerbation events.
Current evidence is inadequate to determine how DPP-4 inhibitors affect the risk of heart failure in patients with type 2 diabetes.
A one-point increase in the American Heart Association's Life's Simple 7 checklist correlated to a 23% lower risk of developing heart failure.
Patients with heart failure who receive the influenza vaccine may have a lower risk for all-cause mortality compared with those who do not get the vaccine.
Researchers found a 15% to 20% reduction in the risk of hospitalization for or death from heart failure in patients who received cardiac resynchronization therapy with defibrillator (CRT-D).
Premature birth has been associated with a number of adverse health conditions.
Chronic heart failure patients who restrict sodium intake may have an increased risk of death or hospitalization.
Researchers have linked pulse pressure to adverse outcomes in heart failure patients with both reduced ejection fraction and preserved ejection fraction.
Researchers examined the effectiveness of diuretic treatment for volume management in patients with chronic heart failure and evidence of worsening congestion.
Researchers on the BEAT-HF trial have concluded that, in patients with chronic heart failure, mirabergron failed to improve left ventricular ejection fraction.
Vericiguat well tolerated but not statistically significant in reducing natriuretic peptide level in patients with chronic heart failureNovember 16, 2015
A phase 2 trial of the drug vericiguat did not show a statistically significant reduction of N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in patients with worsening chronic heart failure.
Elevated total bilirubin, transaminases reported in chronic heart failure patients with poor prognosisNovember 15, 2015
Researchers evaluate the echocardiographic correlates of elevated total bilirubin and transaminases in patients with chronic heart failure.
A study published in The American Journal of Cardiology shows that newer antianginal (AA) medications - including ranolazine - show substantial outcome improvements when compared to traditional AA medications.
Regularly drinking sweetened beverages can increase the risk of heart failure in men by 23% compared with those who do not consume these drinks.
The American College of Cardiology has published a guideline for the management of supraventricular tachycardia (SVT) in adult patients.
Reaching a systolic pressure of 120 mm HG reduces the risk of heart attack, heart failure, and stroke by a third.
Extremely high and low amounts of physical activity increase heart failure risk in men.
Older adults who exercise, drink moderately, don't smoke, and have a healthy weight have a lower risk of heart failure.
Premature ventricular contractions may be a modifiable risk factor for heart failure and death.
Entresto significantly reduced rates of cardiovascular death and hospitalization in heart failure.
Risk prediction model could help determine patients at greater risk for 30-day readmission.